Generic Name and Formulations:
Cefuroxime (as axetil) 250mg, 500mg; tabs.
Indications for CEFTIN:
Susceptible mild to moderate infections including pharyngitis/tonsillitis, acute maxillary sinusitis, bronchitis, acute otitis media; uncomplicated skin and skin structure, UTIs, gonorrhea; early Lyme disease.
≥13yrs: Pharyngitis/tonsillitis, sinusitis: 250mg twice daily for 10 days. Acute bacterial exacerbations of chronic bronchitis, skin and skin structure infections: 250–500mg twice daily for 10 days. Secondary bacterial infections of acute bronchitis: 250–500mg twice daily for 5–10 days. UTIs: 250mg twice daily for 7–10 days. Gonorrhea: 1g as a single dose. Lyme disease: 500mg twice daily for 20 days.
Swallow tab whole, or use susp. Otitis media, sinusitis: 250mg twice daily for 10 days.
Tabs and susp not bioequivalent; do not interchange on a mg/mg basis. Penicillin or other allergy. History of colitis; discontinue if colitis occurs and treat. Renal impairment. Monitor prothrombin time in renal or hepatic dysfunction, stabilized on anticoagulant, poor nutritional state, or long-term use. Labor & delivery. Pregnancy (Cat.B). Nursing mothers: consider discontinuing nursing during treatment.
May cause false (+) Fehling's or Benedict's soln, Clinitest, or Coomb's test. Antacids, others that decrease gastric acidity may inhibit absorption. Potentiated by probenecid. Caution with potent diuretics, other nephrotoxic drugs.
GI disturbances, transient increase of AST, ALT, LDH, eosinophilia, bitter taste; convulsions (overdose).
Tabs—20, 60; Susp 125mg/5mL—100mL; Susp 250mg/5mL—50mL, 100mL
Neurology Advisor Articles
- Clarifying Cardiovascular Risk in Migraine
- Parkinson Disease Symptom Fluctuations Well-Managed With Adaptive Deep Brain Stimulation
- More Evidence Supports Benefits of Cannabidiol for Treatment-Resistant Epilepsy
- Monthly Erenumab Reduces Frequency of Episodic Migraine
- Reduced Risk for Multiple Sclerosis Linked to Greater Sun Exposure
- Tamsulosin Associated With Dementia Risk in Older Patients With BPH
- FDA Approves Blood Test to Assess Concussion
- Gait Difficulty in Parkinson Disease May Be Associated With More Progressive Disease Course
- Tau PET a Useful Biomarker for Alzheimer Disease Risk and Progression
- Multiple Sclerosis Drug Zinbryta Withdrawn From the Market
- Incidence of Delayed Traumatic Intracranial Hemorrhage Low in Older Adults With Blunt Head Trauma
- Older Epilepsy Patients More Likely to Experience AED, Non-AED Drug Interaction
- Female Gender, Natalizumab Exposure Associated With Increased Lymphopenia Risk in FNG-Treated MS
- Accelerated Cognitive Decline Associated With Retinopathy
- Treatment Effects Often Exaggerated in Early Clinical Studies